Tag: CX 2026
Unpacking CREST-2, part two: “It’s a public health benefit to revascularise...
In part two of our special focus on CREST-2, William Gray (Main Line Health, Philadelphia, USA) is once again joined in the CX Studio...
Unpacking CREST-2, part one: Which patient should be treated with which...
In the first instalment of a two-part roundtable discussion on the fallout from CREST-2, William Gray (Main Line Health, Philadelphia, USA) is joined by...
“Incredible results”: C-GUARDIANS II data point to safety and efficacy of...
New findings from the C-GUARDIANS II study indicate that the CGuard Prime carotid stent system (InspireMD) achieves high procedural success, durable early luminal restoration,...
CX 2026: Carotid trial debate highlights “key question” of cost-effectiveness
An audience poll asking, ‘What do we believe: ECST-2 or CREST-2?’ following a debate at the 2026 Charing Cross (CX) Symposium (21–23 April, London,...
